Exploring the Seeds of Innovative Drug Discovery
Through Open Innovation
with Academic-Industrial Research Network

Forerunner Pharma Research (FPR) is a bio-pharmaceutical venture who strives to discover the seeds of innovative drug development by taking advantage of antibody drug development technology based on genome study and disease structure and pathological condition research. With an aim to deliver the latest therapeutic tools, the achievement of cutting edge bio technology, FPR was founded in 2005 at Komaba Open Laboratory of Tokyo University.

Currently, we are active at 4 laboratories, Yokohama Biotechnology Industry Center (YBIC), National Cancer Center (NCC) and Molecular & Life Innovation of Tokyo University (MLI), in addition to Komaba Open Laboratory. While promoting academic-industrial collaborative research of drug discovery based on pathological analysis, FPR try to develop innovative molecular-targeted drug, especially for cancer and immunity, by combining the fruits of its research with Chugai’s proprietary drug development technology.

Drug discovery is a project that requires years of ceaseless efforts, even 10 years or longer. FPR is committed to make a contribution to forward-looking drug discovery through realizing open innovation by further enhancing collaborative research network with domestic and oversea academic research institutes.

More about What we do

Forerunner Pharma Research

Forerunner Pharma Research Co., Ltd.

Address Komaba Open Laboratory,
The University of Tokyo
4-6-1 Komaba, Meguro-ku, Tokyo
153-8904
FAX. +81-3-5452-5772
E-Mail forerunner@chugai-pharm.co.jp